2024年5月24日(金) 13:30 〜 14:45 Room 1 (Hall C)

Chair: Michael Berk (Deakin University)

2024年5月24日(金) 13:30 〜 14:45 Room 2 (Hall B7 (1))

Chair: Rachel A. Hill (Monash University)

2024年5月24日(金) 13:30 〜 14:45 Room 3 (Hall D7)

Chair: Zijun Wang (University of Kansas)

2024年5月24日(金) 13:30 〜 14:45 Room 4 (Hall D1)

Chair: Marco A. Riva (University of Milan), Eri Hashimoto (Sapporo Medical University)

2024年5月24日(金) 13:30 〜 14:30 Room 5 (G409)

Chair: Joseph Zohar (National Post-Trauma Center, Research Foundation by the Sheba Medical Center, Israel)

Symposium outline:
One of the biggest challenges facing clinicians and researchers is to be precise in the medications they use. Our current nomenclature, which is disease-based, uses the terms "antidepressants" and "antipsychotics" (including "second generation" antipsychotics) "mood stabilizers","anxiolytics" etc., which does not do justice to the wealth of neuroscience knowledge that has been accumulated in the past 60 years, since these terms were initially coined.
Prof. Zohar will open the symposia by introducing the growing interest in NbN in the scientific arena, as well as providing a practical demonstration of how to use the search engine of NbN. In the second talk, Prof. Blier will help us dive deeper into the potential of moving to pharmacologically driven concepts by illustrating how taking into consideration the dose of the medication has clear clinical implications in practice and research. In the third talk, Prof. Correll will talk about how using NbN can help to make updated, precise pharmacological steps in the treatment of psychosis. Finally, Dr. Seker will bring the early career voices on NbN from different perspectives, including the perception of the scientific basis for informed prescribing.
In this symposium, there will be ample time for Q&A, which will be led by Prof. Zohar.

2024年5月24日(金) 13:30 〜 14:30 Room 10 (G402)

Chair: Suresh Sundram (Monash University)

Summary:
Panel discussion session with representatives from three to four pharmaceutical manufacturers. This 60-minute session will consist of two parts: oral presentations by representatives of each company and a panel discussion. In the first half of the session, each representative will speak freely about their latest initiatives and future prospects for approximately 10 minutes (no Q&A). After the oral presentations by each company, a panel discussion will be held with representatives as panelists and a chairperson selected from CINP's EC members. The main points of the panel discussion will be presented in advance.

2024年5月24日(金) 15:00 〜 16:00 Room 1 (Hall C)

Chair: Christoph U. Correll (Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA), Tetsuro Kikuchi (Otsuka Pharmaceutical)

2024年5月24日(金) 15:00 〜 16:00 Room 10 (G402)

Chair: Po-See Chen (Department of Psychiatry, National Cheng Kung University Hospital, Tainan, Taiwan), Chau-Shoun Lee (Department of Medicine, MacKay Medical College)

2024年5月24日(金) 15:00 〜 16:00 Room 5 (G409)

Chair: Robert D. Buenaventura (Department of Psychiatry, University of the East Ramon Magsaysay Memorial Medical Center Inc., Quezon City, Philippines)

Abstract:
The global rise in the elderly population, particularly those with dementia, underscores the urgency of addressing the associated challenges. In the Philippines, dementia prevalence among older adults is higher than the regional average, emphasizing the need for effective screening tools. Undetected dementia rates vary globally, necessitating locally validated tools like MMSE-P and MoCA-P. Concurrently, raising awareness about dementia is crucial for early detection.
Further, the complex nature of behavioral and psychological symptoms of dementia (BPSD) requires exploration, considering gene interactions, gender-specific effects, and diverse environmental influences. A study on a Filipino population explored associations between APOE, DRD3, BDNF, and COMT polymorphisms and BPSD endophenotypes, revealing significant associations with APOE, DRD3, and COMT minor alleles. Ethnic variations in genetic risk for BPSD underscore the complex interplay of genetics and environment.
The evolving landscape of Alzheimer's Disease (AD) diagnosis and management involves biomarkers for precise detection, enhancing diagnostic accuracy crucial for emerging disease-modifying therapies. Symptomatic therapies persist, but the promise of slowing AD progression is evident with disease-modifying therapy. The multimodal approach to dementia prevention, considering risk factors and early detection, is paramount. An innovative component incorporated in this intervention is INDAK, which captures the unique culture of Filipinos.

2024年5月24日(金) 15:00 〜 16:00 Room 4 (Hall D1)

Chair: Suresh Sundram (Monash University)